Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

NEJM

June 26, 2023

Enlaces

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Artículos Relacionadas

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study

Evolution of the Primary Aldosteronism Syndrome: Updating the Approach

Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism

Management and follow-up strategies for patients with head and neck paraganglioma

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

✍🏻⚠️ Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Causes, prevention, and management of diabetes-related foot ulcers

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Agenda

Enero 2025

Lun	Mar	Mié	Jue	Vie	Sáb	Dom
30	31	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31	1	2

Top